For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

SNAP-8 (acetyl octapeptide-3): origin, structure and research history

Research Library › Copper & Signal

SNAP-8, listed under the INCI name acetyl octapeptide-3, is a synthetic eight-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) modeled on the N-terminal end of the nerve-terminal protein SNAP-25. It was developed by the Spanish ingredient maker Lipotec, now part of Lubrizol, as a two-residue extension of the earlier hexapeptide Argireline. As of 22 Oct 2026 it is a cosmetic ingredient and is not an FDA-approved drug.

Key facts

TypeSynthetic acetylated octapeptide (8 amino acids)
SequenceAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 (Ac-EEMQRRAD-NH2)
INCI nameAcetyl octapeptide-3
Modeled onN-terminal sequence of SNAP-25
Developed byLipotec (Gavà, Spain), part of Lubrizol since 2012
Regulatory status (Oct 2026)Cosmetic ingredient; not approved as a drug anywhere

Who developed it

SNAP-8 comes from Lipotec, a company founded in 1987 in Gavà, near Barcelona [5]. Lipotec’s peptide line began with Argireline (acetyl hexapeptide-8), designed by Antonio Ferrer-Montiel, Clara Blanes-Mira and colleagues at Miguel Hernández University in Spain together with Lipotec scientists. The patent family was filed with a 1999 priority date, and the first paper appeared in 2002 [3, 4].

SNAP-8 extends the Argireline sequence by two amino acids. Lubrizol, the U.S. specialty-chemicals company, acquired Lipotec in 2012 and continues to supply the ingredient under the Lipotec brand [1, 5, 6].

Structure

SNAP-8 has the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. The N-terminus is acetylated and the C-terminus is an amide, the same end-capping used in Argireline. Its first six residues are identical to Argireline (Ac-EEMQRR-NH2), followed by alanine and aspartic acid [1, 2].

The naming is not fully consistent. The manufacturer’s INCI name is acetyl octapeptide-3, while a 2020 review in Frontiers in Chemistry lists the same sequence as acetyl glutamyl heptapeptide-3 [1, 2].

What it was designed to target

SNAP-8 was designed to mimic the N-terminal end of SNAP-25, one of the proteins that make up the SNARE complex. The SNARE complex is the protein assembly at nerve endings that lets vesicles fuse with the cell membrane and release neurotransmitter. The proposed mechanism is that the peptide competes with native SNAP-25 for a position in this complex [1].

Support for this mechanism comes from laboratory tests and manufacturer data. A 2020 review of cosmetic peptides cited no peer-reviewed clinical study of SNAP-8 [2].

Why it was created

The parent project set out to design a short, non-toxic peptide that interferes with the SNARE complex, the same protein machinery that botulinum neurotoxins disrupt, for use in the cosmetics market [3]. SNAP-8 was developed afterward as a longer analog intended to copy a larger stretch of SNAP-25 [1].

Research timeline

  • 1987: Lipotec founded in Gavà, Spain [5].
  • 1999: Priority date of Lipotec’s patent family on SNAP-25-derived peptides [4].
  • 2002: First peer-reviewed paper on the parent hexapeptide, Argireline [3].
  • 2012: Lubrizol acquires Lipotec [5].
  • 2020: A review in Frontiers in Chemistry finds only laboratory and manufacturer data for SNAP-8 [2].

Regulatory status as of October 2026

As of 22 Oct 2026, SNAP-8 is a cosmetic ingredient and is not approved as a drug in the United States or elsewhere. Under U.S. law, cosmetics and their ingredients, other than color additives, do not need FDA approval before sale, while a product intended to treat or prevent disease can be regulated as a drug [7].

No independent, peer-reviewed human trial of SNAP-8 had been identified as of that date, and the published record consists of laboratory and manufacturer data [2]. SNAP-8 is not named on the 2026 World Anti-Doping Agency Prohibited List [8].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

What is SNAP-8?

SNAP-8 (acetyl octapeptide-3) is a synthetic eight-amino-acid peptide whose sequence is modeled on the start of the nerve-terminal protein SNAP-25. It is supplied as a cosmetic ingredient.

Who makes SNAP-8?

It was developed by Lipotec, a company founded in 1987 near Barcelona. Lubrizol acquired Lipotec in 2012 and supplies SNAP-8 under the Lipotec brand.

What is the difference between SNAP-8 and Argireline?

Argireline (acetyl hexapeptide-8) has six amino acids, Ac-EEMQRR-NH2. SNAP-8 keeps those six and adds alanine and aspartic acid, giving Ac-EEMQRRAD-NH2.

Is SNAP-8 FDA approved?

No. As of 22 Oct 2026, SNAP-8 is a cosmetic ingredient and has not been approved as a drug by the FDA or any other regulator.

Sources

  1. Lubrizol. SNAP-8 peptide solution C (INCI: acetyl octapeptide-3), technical data sheet. SpecialChem, updated 7 Apr 2022. Link
  2. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:572923. Link
  3. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–310. doi:10.1046/j.1467-2494.2002.00153.x. PMID 18498523. Link
  4. Blanes Mira MC, Ferrer Montiel AV, et al. (assignee Lipotec SA). US 7,473,679 B2, Treatments employing neuronal exocytosis-inhibiting peptides; priority 23 Apr 1999. Link
  5. Biocat. Lubrizol Corporation acquires Catalan biotechnology firm Lipotec. 22 Jun 2012. Link
  6. Lubrizol Life Science Beauty. Celebrating 10 years of beauty innovation with Lipotec. Oct 2022. Link
  7. U.S. FDA. FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated. Link
  8. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top